within Pharmacolibrary.Drugs.ATC.J;

model J04AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.25,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Protionamide is a thioamide antibiotic related structurally to ethionamide, used primarily as a second-line agent for the treatment of multidrug-resistant tuberculosis (MDR-TB) and some non-tuberculous mycobacterial infections. It is not widely available in all countries and is not a first-line antituberculous drug.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an average adult patient based on class similarity to ethionamide (due to lack of direct published data for protionamide). Assumed oral administration in adults.</p><h4>References</h4><ol><li><p>Thee, S, et al., &amp; Schaaf, HS (2016). A review of the use of ethionamide and prothionamide in childhood tuberculosis. <i>Tuberculosis (Edinburgh, Scotland)</i> 97 126–136. DOI:<a href=&quot;https://doi.org/10.1016/j.tube.2015.09.007&quot;>10.1016/j.tube.2015.09.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26586647/&quot;>https://pubmed.ncbi.nlm.nih.gov/26586647</a></p></li><li><p>Venkatesan, K (1989). Clinical pharmacokinetic considerations in the treatment of patients with leprosy. <i>Clinical pharmacokinetics</i> 16(6) 365–386. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198916060-00003&quot;>10.2165/00003088-198916060-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2661102/&quot;>https://pubmed.ncbi.nlm.nih.gov/2661102</a></p></li><li><p>Wu, S, et al., &amp; Fan, G (2020). Validation of a universal and highly sensitive two-dimensional liquid chromatography-tandem mass spectrometry methodology for the quantification of pyrazinamide, ethambutol, protionamide, and clofazimine in different biological matrices. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1151 122141–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2020.122141&quot;>10.1016/j.jchromb.2020.122141</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32526663/&quot;>https://pubmed.ncbi.nlm.nih.gov/32526663</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J04AD01;
